479 results on '"Mathijssen, Ron H.J."'
Search Results
2. Intraperitoneal pharmacokinetics of systemic oxaliplatin, 5-fluorouracil and bevacizumab in patients with colorectal peritoneal metastases
3. Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRASG12C-Mutated NSCLC Treated With Sotorasib
4. Staging laparoscopy in gastric cancer patients: From a Dutch nationwide Delphi consensus towards a standardized protocol
5. Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysis
6. Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced EGFR-Mutated NSCLC
7. Quantification and clinical validation of the selective MET kinase inhibitor DO-2 and its metabolites DO-5 and M3 in human plasma
8. Cyclooxygenase-2 inhibition prevents renal toxicity but not hypertension during sunitinib treatment
9. Market Entry Agreements for Innovative Pharmaceuticals Subject to Indication Broadening: A Case Study for Pembrolizumab in The Netherlands
10. The interplay between tamoxifen and endoxifen plasma concentrations and coagulation parameters in patients with primary breast cancer
11. Review – The impact of pharmacogenetics on the outcome of immune checkpoint inhibitors
12. A common germline variant in CYP11B1 is associated with adverse clinical outcome of treatment with abiraterone or enzalutamide
13. Pharmacokinetic boosting of olaparib: A randomised, cross-over study (PROACTIVE-study)
14. Analysis of Serious Weight Gain in Patients Using Alectinib for ALK-Positive Lung Cancer
15. Validation of an LC-MS/MS method for simultaneous quantification of abiraterone, enzalutamide and darolutamide in human plasma
16. Systemic exposure of floxuridine after hepatic arterial infusion pump chemotherapy with floxuridine in patients with resected colorectal liver metastases
17. Local recurrence in primary localised resected gastrointestinal stromal tumours: A registry observational national cohort study including 912 patients
18. Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer
19. Toward model-informed precision dosing for tamoxifen: A population-pharmacokinetic model with a continuous CYP2D6 activity scale
20. Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYD
21. Identifying somatic changes in drug transporters using whole genome and transcriptome sequencing data of advanced tumors
22. Quantitation of osimertinib, alectinib and lorlatinib in human cerebrospinal fluid by UPLC-MS/MS
23. Cardiac Toxicity of Alectinib in Patients With ALK+ Lung Cancer: Outcomes of Cardio-Oncology Follow-Up
24. The course of C-peptide levels in patients developing diabetes during anti-PD-1 therapy
25. CABA-V7: a prospective biomarker selected trial of cabazitaxel treatment in AR-V7 positive prostate cancer patients
26. Clinical utility of circulating tumor DNA in patients with advanced KRASG12C-mutated non-small cell lung cancer treated with sotorasib.
27. Feasibility of therapeutic drug monitoring of sorafenib in patients with liver or thyroid cancer
28. Clinical implications of germline variations for treatment outcome and drug resistance for small molecule kinase inhibitors in patients with non-small cell lung cancer
29. Randomized phase III study of docetaxel versus docetaxel plus intercalated erlotinib in patients with relapsed non-squamous non-small cell lung carcinoma
30. Cross-resistance and drug sequence in prostate cancer
31. Blood-based PD-L1 analysis in tumor-derived extracellular vesicles: Applications for optimal use of anti-PD-1/PD-L1 axis inhibitors
32. Simplified phenotyping of CYP2D6 for tamoxifen treatment using the N-desmethyl-tamoxifen/ endoxifen ratio
33. A phase I dose-escalation and pharmacokinetic study of a micellar nanoparticle with entrapped docetaxel (CPC634) in patients with advanced solid tumours
34. Review – The impact of pharmacogenetics on the outcome of immune checkpoint inhibitors
35. Cyclooxygenase-2 inhibition prevents renal toxicity but not hypertension during sunitinib treatment
36. Reply To the Letter to the Editor by Frugé et al
37. Approach to Alectinib-Induced Body Weight Gain in Patients With ALK+ Non–Small Lung Cancer
38. Quantification of the tyrosine kinase inhibitor erlotinib in human scalp hair by liquid chromatography-tandem mass spectrometry: Pitfalls for clinical application
39. Quantification of afatinib, alectinib, crizotinib and osimertinib in human plasma by liquid chromatography/triple-quadrupole mass spectrometry; focusing on the stability of osimertinib
40. Survival of Patients With Cancer With DPYD Variant Alleles and Dose-Individualized Fluoropyrimidine Therapy—A Matched-Pair Analysis.
41. Design and statistics of pharmacokinetic drug-drug, herb-drug, and food-drug interaction studies in oncology patients
42. Bioanalytical methods for the quantification of hydromorphone, fentanyl, norfentanyl, morphine, morphine-3ß-glucuronide and morphine-6ß-glucuronide in human plasma
43. Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib
44. Pressurized aerosol versus catheter-based intraperitoneal chemotherapy in patients with extensive colorectal peritoneal metastases – comparing results of two early phase trials.
45. Supplementary Table S1 from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer
46. Supplementary Figure S1 from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer
47. Data from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer
48. CCR Translation for This Article from A Long-term Prospective Population Pharmacokinetic Study on Imatinib Plasma Concentrations in GIST Patients
49. Supplementary Data from A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation
50. Supplementary Data from Impact of Concomitant Administration of Gastric Acid–Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.